Table 2 Differences in OS between the CDK4/6i with any ET or AI backbone with the PALOMA-2 sensitivity analysis.

From: Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer

AI backbone

Control

Palbociclib

Ribociclib

Abemaciclib

AI backbone

 Palbociclib

–

0.79 (0.56, 1.14), p = 0.21

0.84 (0.57, 1.24), p = 0.39

 Ribociclib

1.26 (0.88, 1.80), p = 0.21

–

1.06 (0.80, 1.41), p = 0.70

 Abemaciclib

1.19 (0.80, 1.76), p = 0.39

0.95 (0.71, 1.26), p = 0.70

–

Fulvestrant backbone

 Palbociclib

–

0.90 (0.60, 1.33), p = 0.59

0.93 (0.62, 1.40), p = 0.73

 Ribociclib

1.12 (0.75, 1.66), p = 0.59

–

1.04 (0.71, 1.52), p = 0.85

 Abemaciclib

1.08 (0.72, 1.61), p = 0.73

0.96 (0.66, 1.42), p = 0.85

–

PALOMA-2 sensitivity analysis

Control

Palbociclib

Ribociclib

Abemaciclib

 Palbociclib

–

0.87 (0.61, 1.25), p = 0.46

0.93 (0.63, 1.37), p = 0.70

 Ribociclib

1.14 (0.80, 1.63), p = 0.46

–

1.06 (0.80, 1.41), p = 0.70

 Abemaciclib

1.08 (0.73, 1.60), p = 0.70

0.95 (0.71, 1.26), p = 0.70

–

  1. HR (95% CI), p value.
Back to article page